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50 1 | INTRODUCTION 
51 
Abstract 17 
Autophagy  has  emerged  as  a  mechanism  critical  to  both  tumorigenesis  and
18
19 
development  of  resistance  to  multiple  lines  of  anti-cancer   therapy.  Therefore, 20 
targeting autophagy and alternative cell death pathways has arisen as a viable strategy 21 
for refractory tumors. The anti-malarial 4-aminoquinoline compounds chloroquine 22 
and hydroxychloroquine are currently being considered for re-purposing as anti- 23 
cancer therapies intended to sensitize different tumors by targeting the lysosomal cell 24 
death pathway. Here, we describe a novel organometallic chloroquine derivative, 25 
26 
cymanquine,  that exhibits  enhanced bioactivity  compared  to chloroquine in both 27 
normal,  and  reduced  pH  tumor  microenvironments,  thus  overcoming a defined 28 
limitation of traditional 4-aminoquinolines. In vitro, cymanquine exhibits greater 29 
potency than CQ in a diverse panel of human cancer cell lines, including melanoma, in 30 
both normal pH and in reduced pH conditions that mimic the tumor microenvironment. 31 
Cymanquine treatment results in greater lysosomal accumulation than chloroquine and 32 
induces lysosomal dysfunction leading to autophagy blockade. Using a mouse model
33
of vemurafenib-resistant melanoma, cymanquine slowed tumor growth greater than 35 
hydroxychloroquine, and when used in combination with vemurafenib, cymanquine 36 
partially restored sensitivity to vemurafenib. Overall, we show that cymanquine 37 
exhibits  superior  lysosomal  accumulation  and  autophagy  blockade   than  either 38 
chloroquine  or  hydroxychloroquine  in vitro;  and  in addition  to  its high level of 39 
tolerability in mice, exhibits superior in vivo efficacy in a model of human melanoma. 40 
41 
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remnants to  regenerate molecular constituents  for anabolic 50 
metabolism  and to  satisfy energy requirements. Autophagy 51 
52 Autophagy is a catabolic cellular salvage pathway by which 
53 cells degrade and recycle organelles and macromolecular 
involves  initial  sequestration  of  cellular  components  into 52 
membrane-bound vesicles that fuse with low pH lysosomes, 53 
32 
ECTE
D
1 leading to their degradation. Both healthy and malignant cells 
2 utilize autophagy, but in rapidly dividing tumor cells, 
3 autophagy increases to meet survival needs in a nutrient- 
4 deprived microenvironment.1–3 Tumor cells rely on autoph- 
5 agy to develop resistance to various targeted agents and 
6 chemotherapies. For example, the amount of autophagic flux 
7 in melanomas can predict tumor invasiveness, chemothera- 
8 peutic resistance, and patient survival.4 Knockdown of 
9 essential autophagy machinery protein genes forces cell 
10 death in melanoma cells.5 Pharmacological inhibition of 
11 autophagy  re-sensitizes  resistant  tumor  cells  to  primary 
12 targeted therapies.6,7 Thus, inhibiting autophagy might be an 
13 effective way of overcoming drug resistance in various tumor 
14 types.8 
15 The anti-malarial 4-aminoquinoline compounds, chlo- 
16 roquine (CQ), and its derivative hydroxychloroquine 
17 (HCQ), are currently the focus of anticancer repurposing 
18 efforts  for  their  ability  to  inhibit  autophagy  in  various 
19 tumor  types.  CQ  and  HCQ  are  amphipathic  lysosomo- 
20 tropic agents that diffuse through cellular membranes by 
21 virtue of their partial hydrophobic character. Their weak 
22 base properties cause them to become protonated in acidic 
23 milieu. In their charged, protonated state, CQ, and HCQ 
24 become unable to diffuse out of the organelle, causing 
25 accumulation within lysosomes.9 This leads to neutrali- 
26 zation  of  the  lysosomal  lumen,  disruption  of lysosomal 
27 functions including autophagy, and  eventually  lysosomal 
28 membrane  permeabilization,  and   cell   death.10,11  How- 
29 ever,  CQ  and  HCQ  have  an  important  limitation. Solid 
30 tumors with poor vasculature and insufficient blood flow 
31 develop microenvironmental hypoxia, causing them to 
32 primarily utilize hypoxic glycolysis for ATP synthesis, 
33 resulting in acidic extracellular microenvironments 
34 within these solid tumors.12 Low pH significantly 
35 decreases the bioavailable fraction of CQ and HCQ. 
36 Additionally, acidic conditions can induce autophagy in 
37 cells as a means of survival. This limitation has fueled 
38 efforts to develop chloroquine derivatives that can 
39 improve the inhibition of autophagy in acidic tumor 
40 microenvironments.13,14 
41 Bioorganometallic chemistry appeared as a new field 
42 in 1985.15 During its infancy, the field was clearly 
43 overshadowed by the supremacy of research on organo- 
44 metallic catalysts since it was assumed that organometallic 
45 complexes were incompatible with oxygen and water and, 
46 thus, unsuitable for use in biological systems. However, 
47 the bioorganometallic field has flourished with the design 
48 of remarkably bioactive organometallics such as ferro- 
49 quine    (iron-based    antimalarial,    derived    from   CQ),16 
50 ferrocifen   (iron-based   anti-breast   cancer,   derived  from 
51 tamoxifen),17 and Ru-metronidazole (ruthenium-based 
52 bacterial topoisomerase II inhibitor, derived from 
53 metronidazole).18 
We   characterize   the  anticancer   activity   of a  newly 1 
described organometallic CQ derivative  called Cymanquine 2 
(CMQ).19,20 CMQ is a CQ derivative containing a cyman- 3 
trene substitution that  leads to greater  cytotoxic  activity in 4 
vitro to tumor cells compared to traditional quinolines, in both 5 
low and normal pH environments. The  apparent mechanism 6 
for  cytotoxicity  is  supported  by  data  showing  increased 7 
lysosomal accumulation and disruption  of lysosome-depen- 8 
dent  autophagy.  Consistent  with  in  vitro studies showing 9 
greater cytotoxicity, CMQ displays effectiveness as  a single 10 
agent in slowing tumor growth in a mouse model of human 11 
melanoma. 12 
13 
2  |  MATERIALS AND METHODS 14 
15 
2.1  | Synthesis of compounds 16 
17 
Cymanquine  (compound  4,  Figure 1), pseudocymanquine 18 
(compound   5,   Figure   1)   and   ferroquine (compound  3, 19 
20 
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FIGURE  1    CMQ exhibits greater potency than traditional 4- 48 
aminoquinolines and other organometallic CQ derivatives. A, 49 
structures of parent compound CQ: (1) and its derivatives: HCQ; (2), 50 
ferroquine (3); CMQ; (4), pseudo-CMQ; (5),  pseudo-CMQ-O; and 51 
(6). B, cell viability (MTS) assay to determine cytotoxic activity of 52 
test compounds 53 
1 Figure 1) were synthesized as previously described.19,21 A 
2 complete  description  of  the  synthesis  of O-pseudocyman- 
3 quine (pCMQ-O, compound 6, Figure 1) can be found in 
4 Supplementary Information. 
5 
6 2.2 | Cell lines and reagents 
7 
8  Human cancer cell lines ACHN (CRL-1611), BxPC3 (CRL- 
9   1687), DU145 (HTB-81), HT29 (HTB-38), Jurkat (TIB-152), 
10 LNCaP (CRL-1740), PC3 (CRL-1435), SB1A, A375 (CRL- 
11 3224), and T47D (HTB-133) were cultured in RPMI 1640 
12 (Q4Corning-Cellgro #10-1040-CV) supplemented with  10% 
13 FBS (SH30910.3), 1% penicillin/streptomycin/amphotericin B 
14 solution (SV30079.01), 1 mM sodium pyruvate 
15 (SH30239.01), 1% MEM non-essential amino acid solution 
16 (SH30238.1), and 2 mM L-glutamine (SH30034.01) at 37°C in 
17 a  5%  CO2,  humidified  incubator.  All  supplements  were 
18 purchased  from  HyClone™  (Logan,  UT).  The   HPV-18- 
19 transformed  normal  human  prostate  epithelium  cell  line, 
20 RWPE-1 (a gift of Dr. Jane B. Lian, University of Vermont) 
21 was cultured in Keratinocyte-SFM (Thermo Fisher Scientific 
22 #17005-042) supplemented with 5 ng/mL human recombinant 
23 epidermal growth factor (Thermo Fisher Scientific 
24 #PHG0311),  and  50 μg/mL  bovine  pituitary  extract (Life 
25 Technologies #13028014) at 37°C in a 5% CO2,  humidified 
26 incubator. All cancer cell lines were acquired from the 
27 American Type Culture Collection with the exception of 
28 SB1A, which has been described previously.22 All cell line 
29 cultures were tested as negative for Mycoplasma contamina- 
30 tion using the MycoAlert Mycoplasma Detection Kit (Lonza 
31 #LT07-118), and were used for experimentation within five 
32 passages of thawing. Chloroquine diphosphate (MP Biomed- 
33 icals, LLC #193919) and hydroxychloroquine (Selleck 
34 Chemicals #S4430) stock solutions were prepared in water, 
35 and  organometallic compounds were  all  prepared  in dime- 
36 thylsulfoxide (DMSO, EMD Millipore #MX1458-6), all at a 
37 concentration of 10 mM. Vemurafenib-resistant A375 mela- 
38 noma cells were generated by plating A375 cells in a 10 cm 
39 dish in the presence of increasing concentrations of Vemur- 
40 afenib (LC Laboratories #V-2800) in DMSO, starting with 
41 1 μM. Resistant clones were maintained in 2 μM Vemurafenib. 
42 
43 2.3 | Cytotoxicity assay 
44 
45 Cells were plated in quadruplicate in 96-well tissue culture 
46 plates (Falcon) at a density of 2000-5000 cells per well 
47 (depending upon growth rate of cell line) in a volume of 
48 100 μL growth media. Cells were then incubated in the 
49 presence of test compounds for 72 h. Viability was 
50 measured by the CellTiter 96 aqueous non-radioactive 
51 cell proliferation assay (Promega, Madison, WI, #G5430) 
52 per manufacturer's instruction. Absorbance was measured 
53 on a Perkin-Elmer Victor ×4 multi-label plate reader. 
Absorbance  data  was  fit  to  a  four  parameter  inhibitor 1 
response model using  Prism software (GraphPad Software, 2 
La  Jolla,  CA)  to  obtain  IC50 values  and  normalization 3 
parameters. Statistical analyses were also performed using 4 
Prism software. 5 
6 
2.4 | Western blotting 7 
8 
See Supplementary Information for a complete description of 9 
Western blotting methods and materials. 10 
11 
2.5 | Flow cytometry 12 
13 
For  concurrent  lysosomal  staining  and  cytotoxicity  mea- 14 
surement,   a   flow   cytometric   adaptation   of   previously 15 
published  methods23  was  employed.  For measurement of 16 
autophagic flux, a fluorescent   reporter (DsRed-LC3-GFP)- 17 
based  flow  cytometry  method  was  used as described.24,25 18 
The retroviral plasmid used for expression of the reporter, 19 
pQCXI-Puro-DsRed-LC3-GFP,   was   a   gift  from  David 20 
Sabatini   (Addgene   plasmid   #  31182).   A more  detailed 21 
description  of  the method employed  here  can  be found in 22 
Supplementary Information. 23 
24 
2.6 | Fluorescence microscopy 25 
26 
To achieve expression of fluorescent-labeled  LC3 to enable 27 
fluorescence  microscopy  detection  of subcellular localiza- 28 
tion, an exogenous EGFP-LC3 fusion construct was obtained 29 
as a gift from Karla Kirkegaard (Addgene plasmid #11546).26 30 
The   plasmid   was   transfected   into   cell   line PC3  with 31 
Lipofectamine   3000   reagent   (Thermo  Fisher  Scientific 32 
#L3000008), expanded under neomycin selection, and plated 33 
on Nunc Lab-Tek II chamber slides. Cells were  treated with 34 
drugs  for  6 h  prior  to  washing  and  fixation  using  2% 35 
paraformaldehyde in PBS. Cells were visualized on a Zeiss 36 
Axio  Imager  2  fluorescence  microscope  equipped with a 37 
Hamamatsu CCD camera. 38 
39 
2.7 | Lysosome isolation 40 
41 
Briefly, lysosome isolation was carried out by differential 42 
centrifugation. See Supplementary Information for a com- 43 
plete description of Lysosome Isolation. 44 
45 
2.8 | Liquid chromatography/mass 46 
spectrometry 47 
48 
Quantitation of test compounds from biological materials was 49 
performed by high performance liquid chromatography/mass 50 
spectrometry (HPLC-MS/MS). For a detailed  description of 51 
methods    used    for    HPLC-MS/MS, see   Supplementary 52 
Information. 53 
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1 2.9 | Animal models 
2 All   animal   work   was   performed   under   approval   and 
3 supervision of the University of Vermont Institutional Animal 
4 Care and Use Committee (IACUC). A complete description 
5 of  methods  involving  animal  models  can  be  found  in 
6 Supplementary Information. 7 
8 
9 3 | RESULTS 
10 
11 3.1 | CMQ exhibits more potent cytotoxicity 
12 compared to CQ and other quinoline 
13 derivatives 
14 
15 To  examine  if  novel  organometallic  substitutions  on  the 
16 quinoline  framework  could  confer  increased  efficacy  in 
17 low  pH  environments,  we  tested  a  panel  of  traditional 
18 quinolines, CQ (compound 1) and HCQ (compound 2), and 
19 several novel organometallic CQ derivatives, whose struc- 
20 tures  are shown in  Figure  1A. Our  previous  experience in 
21 replacing   a   ferrocene   group   by   a   cymantrenyl  center 
22 (CpMn(CO)3)27 prompted us to prepare cymanquine based 
23 on the previously described ferroquine (FQ, compound 3). 
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CMQ has greater potency than CQ in  both normal 2223
24 Therefore, we tested the potent antimalarial organometallic 
25 quinoline, FQ, which is  an effective agent for targeting CQ- 
26 resistant malarial parasites,21 but for which mammalian anti- 
27 cancer  activity  has  not  been  described.  We  tested  CMQ 
28 (compound   4).   We  then   also   prepared   analogues with 
29 decreased basicity such as a CMQ derivative in which one 
30 of  the  basic  group,  the  trimethylamine  group  has  been 
31 removed (termed pseudocymanquine, or p-CMQ; compound 
32 5), and a 4-oxoquinoline derivative of p-CMQ termed pCMQ- 
33 O (compound 6) where two basic sites have been removed 
34 (the triethylamine and the aniline groups.We measured the 
35 cytotoxic activity of these compounds in the melanoma cell 
36 line A375 (Figure 1B). Results from this strategy showed that 
37 both FQ and CMQ displayed a lower IC50 than CQ or HCQ by 
38 at least an order of magnitude, with CMQ showing the highest 
39 potency of all compounds tested. 
40 
41 3.2 | CMQ exhibits greater potency than CQ 
42 in both normal and low pH environments 
43 
44 We systematically treated cell lines grown in both normal and 
45 low pH conditions with a range of CMQ or CQ concen- 
46 trations. After 72 h of exposure to drug, cell viability was 
47 assessed by the MTS assay. Viability curves like those shown 
48 in Figure 2A were fit to an inhibition model to determine the 
49 IC50. As summarized in Figure 2B, and detailed in Table 1, 
50 CMQ exhibited more greater potency than CQ across all cell 
51 lines tested, as indicated by lower pairwise IC50 values in both 
52 normal and low pH settings. The IC50 offset created by 
53 low pH conditions was not observed for CMQ to the extent 
and low pH environments in diverse human cancer cell  lines. A, 
representative dose-response cell viability assay (MTS  assay) for 24 
human lymphoma cell line, Jurkat, exposed to CMQ, and CQ for 25 
72 h, in normal and low pH settings (mean ± SEM [n =  4]). B, 26 
aggregate IC50 values in a diverse panel of cell lines in both normal 27 
and low pH settings after 72 h of exposure to CMQ and CQ. Symbols 28 
represent best-fit IC50 values. Lines represent mean and 95% 29 
confidence intervals. Paired t-tests were performed  to evaluate 30 
statistical significance (*P < 0.05). #, Culturing of this cell  line was 31 
not amenable to low pH conditions 32 
33 
34 
that it  was for CQ.  The normal prostate epithelial  cell line, 35 
RWPE-1, was included to show relative sensitivity compared 36 
to transformed cell lines. RWPE-1 was most resistant to both 37 
CQ and CMQ exposure, suggesting that transformed cells are 38 
more dependent upon autophagy than their non-transformed 39 
counterparts.  However,  we  cannot  rule  out differences in 40 
sensitivity being owed to differences in the formulations in 41 
the growth media employed. CQ displayed an average IC50 of 42 
26.1 µM for all cell lines tested at normal pH, and an average 43 
of 141 µM at low pH. CMQ displayed an average IC50 of 44 
7.53 µM at normal pH, and an average of 14.2 µM at low pH. 45 
These findings suggest that CMQ may act as a more potent 46 
lysosomal  inhibitor  in  bulky  solid  tumors,  where  tumor 47 
interior acidification has been observed to augment autopha- 48 
gic flux, particularly in melanoma.12 We hypothesize that the 49 
comparatively higher activities observed for CMQ versus CQ 50 
are  due  to  the  aforementioned  pKa differences and corre- 51 
spondingly   higher   bioavailable   fractions   of   the   drug 52 
(uncharged  CMQ)  at  both  pH  values  tested.  This  is  of 53 
1 TABLE 1   Potency (IC50 (95% confidence limits) of CQ versus CMQ in cell lines grown in normal and low pH conditions 1 
2 2 
3 3
4 4 
5 5 
6 6
7 7 
8 8 
9 9 
10 10 
11 11 
12 12
13 13
14 14 
15 aAmbiguous fit to inhibition model did not permit finite determination of 95% confidence intervals. 15 
16 bThe RWPE1 cell line was not compatible with low pH growth conditions. 16 
17 17 
18 18 
19 particular importance since low pH conditions have been 
20 identified as a major in vivo limitation for CQ and HCQ.12 
21 
22 3.3 | CMQ has greater lysosomotropic activity 
23 than CQ 
24 
25 Since our in vitro cytotoxicity studies demonstrated that CMQ 
26 outperforms traditional quinolones at killing cancer cells, we 
27 sought to determine whether CMQ shared a similar 
28 mechanism of action with CQ and HCQ. CQ and HCQ 
29 accumulate in lysosomal compartments and disrupt lyso- 
30 somal functions, including lysosome-associated autophagy, 
31 although these compounds may also be inhibiting other 
32 cellular processes that are dependent upon lysosomal 
33 integrity.28,29 To determine whether differences between 
34 CMQ and CQ cytotoxic activity were due to biovailability and 
35 subsequent accumulation of these compounds in various 
36 cellular compartments, we used a cell fractionation approach 
37 coupled with high sensitivity measurement of drug analytes 
38 by HPLC-MS/MS. Figure 3A demonstrates the extent of 
39 lysosomal enrichment achieved from SB1A melanoma cells 
40 treated for 16 h with 1 μM CMQ or CQ, using differential 
41 ultracentrifugation. The lysosomal marker LAMP2 was used 
42 as an indicator of enrichment from fractions with equal total 
43 protein content. These fractions of equal total protein content 
44 were then analyzed by HPLC-MS/MS to determine drug 
45 concentrations  in  each  fraction.  CMQ  had  over  50-fold 
46 greater accumulation in lysosomes than CQ and over six-fold 
47 greater accumulation in whole cell and nuclear fractions 
48 (Figure 3B). 
49 We co-stained treated cells with the lysosomotropic 
50 fluorophore NBD-PZ and propidium iodide to simulta- 
51 neously measure lysosomal content and cell viability by 
52 flow cytometry, and applying a gating algorithm as shown 
53 in Figure 3C. Live cells were sorted based on the absence of 
propidium iodide staining (Figure 3C, left panel). Live cells, 19 
analyzed for staining with the lysosomotropic fluorophore 20 
NBD-PZ, showed higher fluorescence intensity  in  cells  21 
treated with CMQ and correspondingly, higher lysosomal 22 
accumulation (Figure 3C, right panel). Treatment with low 23 
micromolar concentrations of CMQ caused significant 24 
cytotoxicity within 24 h, not merely cytostatic activity as 25 
evidenced by the presence of  dead  (PI  positive)  cells,  26 
whereas treatment with CQ did not (Figure 3D).  CMQ-  27 
induced cytotoxicity is accompanied by significantly higher 28 
lysosomal accumulation compared to  CQ  treated  cells 29 
(Figure 3E), as measured by NBD-PZ median fluorescence 30 
intensity. As stated, at the highest concentration of CMQ 31 
tested,  NBD-PZ  fluorescence  intensity  becomes  reduced,  32 
and not significantly different  from  CQ,  because  of 33 
increasing cell death with CMQ. This approach cannot 34 
discriminate between decrease in lysosomal content and an 35 
increase in lysosomal pH,  since  emission  of  NBD-PZ 36 
depends on both fluorophore concentration and pH. The 37 
possibility exists that lysosomal content is increased by high 38 
CMQ concentrations but the lysosomal lumens are 39 
simultaneously becoming neutralized. Despite  this  caveat,  40 
the results show that CMQ accumulates in cells to a greater 41 
extent than CQ when cells are exposed to equimolar 42 
concentrations of either drug, and that the lysosomes appear  43 
to be the primary site of accumulation of both drugs. 44 
Additionally, CMQ exposure causes an accumulation of 45 
lysosomes in living cells and has more  potent  cytotoxic  46 
activity than CQ over a 24 h period. 47 
48 
3.4 | CMQ disrupts lysosome-dependent 49 
autophagy 50 
51 
Lysosomal function is required for autophagy to proceed. We 52 
used the conventional method of following the accumulation 53 
Cell line CQ pH 7.20 CMQ pH 7.20 CQ pH 6.62 CMQ pH 6.62 
ACHN 34.1 (18.0-64.4) 10.1 (8.16-12.6) 201 (Very wide)a 41.3 (34.8-49.1) 
BxPC3 17.7 (15.8-19.9) 5.94 (5.55-6.35) 75.5 (55.1-103) 7.18 (6.49-7.96) 
DU145 71.5 (63.1-80.9) 11.1 (10.1-12.9) 197 (156-248) 28.5 (21.2-38.4) 
HT29 14.5 (9.56-21.9) 3.78 (2.88- 4.97) 99.6 (65.4-152) 6.64 (5.10-8.64) 
Jurkat 12.2 (10.5-14.2) 5.18 (4.52-5.95) 92.3 (66.8-128) 11.5 (9.51-13.8) 
LNCaP 75.0 (62.2-90.4) 14.9 (13.2-16.8) 165 (110-248) 12.2 (9.99-14.8) 
SB1A 16.1 (9.77-26.6) 2.23 (1.88-2.64) 105 (Very wide) 6.34 (6.12-6.62) 
PC3 23.2 (11.6-47.4) 12.5 (10.4-15.1) 154 (118-201) 21.5 (16.4-28.1) 
T47D 27.6 (15.3-49.9) 14.0 (9.37-20.9) 145 (137-154) 20.0 (16.6-24.2) 
RWPE1 110 (106-114) 43.9 (40.4-47.8) N/Ab N/Ab 
PRO
O 
UNCORRECTED
1 1 
2 2 
3 3 
4 4 
5 5 
6 6 
7 7 
8 8 
9 9 
10 10 
11 11 
12 12 
13 13 
14 14 
15 15 
16 16 
17 17 
18 18 
19 19 
20 20 
21 21 
22 22 
23 23 
24 24 
25 25 
26 26 
27 27 
28 28 
29 29 
30 30 
31 31 
32 32 
33 33 
34 34 
35 35 
36 36 
37 37 
38 FIGURE 3    CMQ displays greater lysosomal accumulation than CQ. SB1A melanoma cells treated with 1 μM CQ or CMQ for 24 h, 38 
39 
underwent cellular fractionation by differentiation centrifugation. A, fractionation was confirmed by Western blot. B, drug concentration in each 39 40 
fraction was quantified via HPLC-MS/MS analysis. C, after 24 h of exposure to 5 μM CMQ or CQ, SB1A cells were simultaneously stained with 40 41 
NBD-PZ and propidium iodide and analyzed by flow cytometry. Live cells were sorted based on absence of propidium iodide staining (left 41 42 
panel, pentagonal gate), then analyzed for NBD-PZ staining (right panel), which is indicative of lysosomal content. D, dose-response cell 42 43 
viability curves after exposure to various concentrations of CQ and CMQ measured as percentage of live cells (negative for propidium iodide 43 
44 
staining). E, NBD-PZ median fluorescence intensity reflecting lysosomal content and acidity, as NBD-PZ emission depends on pH. Data in (D 44 
45 and E) presented as mean ± SEM (n = 3). *P < 0.05 and **P < 0.001 by student's t-test 45 
46 46 
47 47 
48 of ubiquitin-like autophagy-related proteins and autophagy 
49 cargo adapter proteins to survey autophagic flux in cells 
50 treated with either CQ or CMQ. Lipidation of the ubiquitin- 
51 like proteins microtubule associated protein-light chain 3 
52 (MAP-LC3, or referred to here as LC3) and γ-aminobutyric 
53 acid-type-A-receptor-associated protein (GABARAP) are 
important steps in autophagosome elongation.30 It is well 48 
established that elongation steps becomes stalled in the 49 
presence of lysosomotropic agents, like CQ and HCQ.31,32 50 
Additionally,   trafficking   of   specified   substrates  to  the 51 
autophagosome  is  carried  out  by  cargo  adaptor  proteins, 52 
such  as  p62/SQSTM1  (hereafter  referred  to  as p62), that 53 
PRO
O 
UNCORRECTED
40 
performed to determine LC3-II/I and GABARAP-II/I ratios and p62 accumulation. Bars represent mean values ± SEM from three replicate 40 
41 
experiments (*P < 0.05). #, indicates cell death. C, PC-3 cells stably expressing EGFP-LC3 were treated with CQ or CMQ for 4 h prior to 41 
42 
fluorescence microscopy evaluation of EGFP-LC3 subcellular deposition. Punctate LC3 distribution is indicative of autophagy blockade. D,
 42 authopagic flux was evaluated by flow cytometry-based measurement of DsRed-LC3-GFP reporter fluorescence as a consequence of CQ or 
43 
CMQ treatment. Cells were treated with indicated concentrations of drugs 24 h prior to analysis. Bars represent mean values ± SEM from three 43 
44 
replicate experiments (*P < 0.05) 44 
45 45 
46 46 
47 accumulate upon autophagy disruption. We monitored this 
48 process by Western blot to observe the effects of CMQ on 
49 accumulation of lapidated isoforms of LC3 and GABRAP 
50 (LC3-II, and GABARAP-II, respectively), and overall p62 
51 levels using CQ as a positive/comparative control. SB1A cells 
52 were treated with various concentrations of CMQ or CQ  for 
53 24 h  prior  to  western  analysis.  CMQ  treatment  results in 
higher levels of LC3-II, p62, and GABARAP-II accumulation  47 
at lower concentrations  compared  to  CQ  as  shown  in  48  
Figure 4A. Quantitative analysis of Western blot data was 49 
performed (Figure 4B) shows that significantly higher ratios    50 
of  LC3-II/LC3-I  and  GABARAP-II/GABARAP-I,  and  p62    51 
levels are obtained in cells treated with CMQ compared to  52  
CQ, at 10 μM final concentrations. Excessive cell death was 53 
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39 of CQ or CMQ for 24 h prior to Western blotting for LC3 and GABARAP isoforms I and II, and for p62. B, densitometry of protein bands was 39 
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1 observed in cells treated with 100 μM CMQ (marked with # 
2 symbol) which led to highly inconsistent results. 
3 To further assess autophagy disruption, PC-3 prostate 
4 cancer cells, which stably express the fluorescent EGFP-LC3 
5 fusion protein, were treated with concentrations of either CQ 
6 or  CMQ  for  4 h  prior  to  visualization  by  fluorescence 
7 microscopy.  CMQ  altered  the  subcellular  distribution   of 
8 EGFP-LC3 fusion protein resulting in punctate EGFP-LC3 
9 emission pattern, which is a hallmark of autophagy blockade 
10 attributable to lysosomal dysfunction33 (Figure 4C). CMQ 
11 and CQ both exhibited punctate LC3 distribution, but the 
12 appearance of LC3 puncta are visible at lower CMQ 
13 concentrations, consistent with more potent autophagy 
14 blockade. 
15 As a last measure of autophagy disruption, we monitored 
16 changes in autophagic flux resulting from CQ or CMQ 
17 treatment using a flow cytometry-based fluorescent LC3 
18 reporter assay.24 In this assay, a dual labelled LC3 reporter 
19 (DsRed-LC3-GFP) is stably expressed to allow concomitant 
20 measurement of autophagic proteolytic activity and internal 
21 normalization to overall LC3 expression. In untreated cells 
22 the GFP tag is selectively proteolyzed through autophagy. As 
23 shown in Figure 4D, treatment of SB1A cells stably 
24 expressing the DsRed-LC3-GFP reporter showed increasing 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
levels of normalized GFP fluorescence when treated with CQ 1 
or CMQ, indicative of reporter accumulation as a result of 2 
autophagy   inhibition.   CMQ   showed significantly  higher 3 
levels of GFP accumulation than CQ at concentrations greater 4 
than 0.1 μM. 5 
These results demonstrate that CMQ  disrupts lysosome- 6 
dependent autophagy, which may induce cell death through 7 
lysosome-mediated cell death pathways. 8 
9 
3.5 | CMQ displays single agent anti-tumor 10 
activity in a mouse model of  human melanoma 11 
12 
The promising anti-cancer properties displayed by CMQ in 13 
vitro led us  to ask  whether  the compound  would   be both 14 
tolerated  and  have  activity  in  vivo,  in  mouse  xenograft 15 
models. Tolerability was assessed using a dose escalation 16 
method with animals receiving doses injected IP on a 3-day- 17 
on/2-day-off schedule for a total of 12 days. At all dose levels 18 
tested,   we   observed   no   behavioral, gross  physiological 19 
changes, or deaths that would prompt removal of the animals 20 
from the experiment. No statistically significant body mass 21 
changes were observed (Figure 5A). A trend of body mass 22 
loss was observed for the 100 nmole/g cohort, however, this 23 
loss was not found to be statistically significant, nor was it 24 
25 
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48 FIGURE 5    CMQ is superior to HCQ as single agent therapy for melanoma in mouse model. A, MTD determination was attempted in female 48 
49 Nu/Nu by a dose escalation strategy whereby body mass was monitored to detect adverse body mass loss. B, A375 xenografts were created in 49 
50 Nu/Nu mice. Efficacy of single agent therapy with CMQ, HCQ, or vehicle on tumor growth. Symbols represent mean tumor volumes ± SEM. C, 50 
51 rates of tumor growth for each drug as a single agent indicate superior efficacy by CMQ on tumor growth. D, relative tumor volumes at endpoint 51 
52 (14 days of treatment) were calculated. In (C and D) lines represent mean ± SEM. Unpaired t-tests were performed to determine statistical 52 
53 significance (*P < 0.05) 53 
1 observed at the higher dosing level of 140 nmole/g. The dose 
2 escalation experiment did not capture the MTD for CMQ, as 
3 we  did  not  exceed  140 nmole/g  due  to  solubility  issues. 
4 Therefore, all subsequent in vivo experimentation  involving 
5 CMQ and HCQ was performed at this dosing level. 
6 To assess efficacy of CMQ as an anti-cancer therapeutic, 
7 we  generated  vemurafenib-resistant  A375  (A375VR) xeno- 
8 graft tumors in female Nu/Nu mice and randomly assigned 
9 these mice into three treatment arms: vehicle (n = 4), HCQ 
10 (n = 5), and CMQ (n = 6). Both HCQ and CMQ significantly 
11 slowed tumor growth compared to vehicle, with CMQ 
12 exhibiting slight improvement over HCQ (Figure 5B). Tumor 
13 growth inhibition was evaluated by a growth rate analysis 
14 approach 34. HCQ significantly decreased the rate of tumor 
15 growth compared to vehicle, but CMQ showed a greater 
16 magnitude of tumor growth inhibition compared to both 
17 vehicle and HCQ (Figure 5C). The mean tumor volume by 
18 day 14 of treatment (endpoint) was 1251 mm3 for the vehicle 
19 group, 869.9 mm3 for HCQ group, and 275.3 mm3 for the 
20 CMQ group. Analysis of relative tumor volumes at endpoint 
21 (Figure 5D) showed that both HCQ and CMQ reduced final 
22 tumor volumes at endpoint. 
23 
24 3.6 | CMQ restores sensitivity in vemurafenib- 
25 resistant melanoma 
26 
27 Since CMQ exhibited greater potency than CQ and HCQ as a 
28 single agent, we also evaluated whether CMQ could reverse 
29 drug resistance. BRAFV600E-positive human melanoma cell 
30 line A375 P(A375P denotes parental line) was exposed to 
31 progressively increasing concentrations of vemurafenib over 
32 a course several months to create a vemurafenib-resistant cell 
33 line (A375VR). Resistance was confirmed by evaluating 
34 vemurafenib sensitivity in a viability/cytotoxicity assay, 
35 where we observed an increase in vemurafenib IC50 from 
36 approximately 300 nM to greater than 30 μM (Figure 6A). To 
37 determine if drug resistance could be reversed by CMQ, as 
38 has been reported for HCQ,7 vemurafenib sensitivity of 
39 A375VR was re-determined in the presence of various 
40 concentrations of HCQ or CMQ. Both CMQ and HCQ 
41 were able to partially restore sensitivity to vemurafenib 
42 (Figure 6A); however, CMQ showed a greater ability to 
43 reverse vemurafenib resistance at lower concentrations than 
44 HCQ (Figure 6). 
45 To evaluate if CMQ can restore vemurafenib sensitivity 
46 in vivo, we tested combination therapies in a xenograft 
47 model of vemurafenib resistance. All mice received 
48 vemurafenib once tumor volumes reached 100 mm3 plus 
49 either vehicle (n = 4), HCQ (n = 4), or CMQ (n = 5). The 
50 rate of tumor growth of mice treated with vehicle plus 
51 vemurafenib was higher than those treated with vemur- 
52 afenib plus either HCQ or CMQ (Figure 6C). While the 
53 combination of HCQ or CMQ with vemurafenib both 
slowed tumor growth compared  to  vemurafenib  alone, the 1 
rate of tumor growth was slowed to a greater extent in mice 2 
treated with vemurafenib plus CMQ (Figure 6D). The mean 3 
relative tumor size by day 14 of treatment (endpoint) was 4 
850 mm3  for  the  vemurafenib-alone  group,  compared  to 5 
326 mm3  and  281 mm3  for  vemurafenib  plus  HCQ  and 6 
Vemurafenib plus CMQ, respectively. Analysis of relative 7 
tumor volumes at endpoint (Figure 6E) showed that while 8 
both  HCQ  and  CMQ  appeared  to  reduce  final  tumor 9 
volumes   at    endpoint,    neither   achieved  the   statistical 10 
significance    threshold    implemented    (P < 0.05).   CMQ 11 
nearly reached this threshold value with P = 0.052. 12 
13 
14 
4 | DISCUSSION 15 
16 
Autophagy plays decisive roles in tumor progression, tumor 17 
adaptation,   and   drug   resistance.  The   use of  weak-base 18 
lysosomotropics  is  being  tested  in  clinical  trials  to  slow 19 
tumor growth, boost therapeutic efficacy, and reverse drug 20 
resistance.35–39  The  weak  base  character  of many lysoso- 21 
motropic  inhibitors  represents  a  worrisome limitation for 22 
these drugs, as they are much less potent in acidic milieu.12 23 
CMQ   shares   structural  and   chemical similarities  to  the 24 
novel  antimalarial  compound,  ferroquine  (FQ) which has 25 
displayed    promising    results    in treating   drug-resistant 26 
malaria.40,41  The  application  of  FQ  as anticancer therapy 27 
has  not  been  reported  at  the  time  of  this  report.  The 28 
ferrocene substitution  in FQ  causes  a reduction in the pKa 29 
and an increase in the lipophilicity of the drug compared to 30 
CQ  at  normal  pH.42  We  hypothesized  that a cymantrene 31 
substitution  would  manifest  as  higher  potency  at  both 32 
normal  and  reduced pH conditions. 33 
To  test  our  hypothesis,  we  examined  a  panel of both 34 
traditional, and novel organometallic quinoline compounds to 35 
gauge efficacy  as anticancer therapeutics. Our  results show 36 
that,  generally,  organometallic  quinolines  possess  greater 37 
anti-growth  properties  than  the traditional quinolines, with 38 
CMQ displaying superior potency in vitro compared to all 39 
compounds tested. The relative cytotoxic activity of p-CMQ 40 
was   rather   unexpected,   because   of   the  importance  of 41 
intramolecular hydrogen bonding between the 4-amino and 42 
terminal trimethylamine having been reported in  FQ, aiding 43 
the diffusion through the hydrophobic membranes.16 Allevi- 44 
ation of the un-partnered H-bond donor, the 4-amino group, in 45 
this context, through substitution with an oxygen atom at this 46 
position, might be expected to restore activity. However, we 47 
observed the opposite effect. Both compounds lacking the 48 
terminal trimethylamine group displayed what we interpreted 49 
as cytostatic activity, as opposed to cytotoxic activity. This 50 
interpretation stems from the steepness of the viability curves, 51 
with CMQ, FQ, HCQ, and to a lesser extent, CQ having steep 52 
curves, and p-CMQ and p-CMQ-O having sweeping shallow 53 
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37 FIGURE 6    CMQ partially restores sensitivity to Vemurafenib in resistant melanoma cells in vivo. A, MTS cytotoxicity assay confirms 37 
38 vemurafenib resistance in A375, as reflected by increased IC50 in A375VR compared to A375 parental line (A375P). This assay illustrates how 38 
39 addition of HCQ or CMQ affects vemurafenib sensitivity in A375VR cells. B, HCQ and CMQ both partially restore sensitivity to vemurafenib at 39 
40 various concentrations. C, Nu/Nu mouse A375VR xenograft model was used to compare efficacy of HCQ versus CMQ in combination with 40 
41 Vemurafenib on tumor growth. Symbols represent mean tumor volumes ± SEM. D, rates of tumor growth for combination therapy of 41 
42 vemurafenib plus either HCQ or CMQ. Symbols represent best-fit rate constant values of individual tumors. E, relative tumor volumes at 42 
43 endpoint (14 days of treatment) were calculated. In (D and E) lines represent mean ± SEM. Unpaired t-tests were performed to determine 43 
44 statistical significance (*P < 0.05) 44 
45 45 
46 curves indicating progressive growth inhibition over the 
47 concentration range spanning the curve (Figure 1). 
48 We compared CMQ's efficacy to that of CQ in a diverse 
49 panel of cancer cell lines selected for their ability to adapt 
50 and grow in RPMI-1640 supplemented with 10% FBS 
51 (Figure  2).  Identical  growth  conditions  were  essential for 
52 our  analysis  since  we  postulated  that  CMQ  may  inhibit 
53 autophagy in a manner similar to CQ and HCQ, and since it 
has been well-established that cellular metabolism, particu- 46 
larly autophagy, is sensitive to nutrient availabilities and 47 
concentrations. Furthermore, RPMI-1640 is a  favorable  48 
growth medium as it contains  lower glucose  content  than  49 
other common growth base media, thus favoring autophagy. 50 
Lastly, we were able to modify this medium with PIPES to 51 
reproducibly buffer the pH at  6.62  to  create  growth  52 
conditions that mimic the interior of bulky solid tumors. 53 
1 Using this approach, we observed a consistently lower 
2 pairwise IC50 value for CMQ compared to CQ in each cell 
3 line tested, and that low pH conditions, which diminish CQ 
4 activity, have a lesser effect on CMQ. These findings 
5 suggest that CMQ may act as a more potent lysosomal 
6 inhibitor in bulky solid tumors, where tumor interior 
7 acidification has been observed to augment autophagic 
8 flux, particularly in melanoma.12 We hypothesize that the 
9 comparatively higher activities observed for CMQ versus 
10 CQ are due to the aforementioned pKa differences and 
11 correspondingly higher bioavailable fractions of the drug 
12 (uncharged CMQ) at both pH values tested. This is 
13 particularly important since low pH conditions are a major 
14 in vivo limitation for CQ and HCQ.12 We observed that 
15 those cells most sensitive to CQ exposure were similarly 
16 most sensitive to CMQ, whereas those most resistant to CQ 
17 were also most resistant to CMQ, implying that both drugs 
18 utilize a similar mechanism of action. 
19 A partial understanding of the mechanism of action of 
20 antimalarial quinoline compounds in mammalian cells has 
21 been in place for decades,10,43 where it was appreciated that 
22 these compounds possessed the capacity to disrupt 
23 lysosomal function. This led to their repurposing in the 
24 anti-inflammatory armamentarium, where the mechanism of 
25 action was elaborated to include disruption of antigen 
26 processing  through  endosome  acidification,44  as  well   as 
27 inhibit  Toll-like  receptor  signaling.45  Only  more recently 
28 has the consideration of re-purposing of lysosomotropic 
29 compounds entered the anti-cancer field. Disruption of 
30 lysosome-dependent autophagy might be therapeutically 
31 important, because autophagy is activated in disease 
32 progression and severity. The traditional quinolines impact 
33 tumor growth primarily through autophagy blockade. Our 
34 results show that CMQ maintains the lysosomotropic and 
35 anti-autophagy activities of its predecessor molecules, but 
36 surpasses them in its ability to accumulate in lysosomes and 
37 to prevent autophagy flux (Figure 3). 
38 For CMQ to be considered a viable alternative to CQ or 
39 HCQ as an anti-cancer therapy, it must be tolerated, and 
40 slow tumor growth in vivo. Our in vivo results demonstrate 
41 that CMQ is effective as a single agent in slowing growth of 
42 vemurafenib-resistant, BRAFV600E-positive human mela- 
43 noma tumors (Figure 5). Although in vitro results showed 
44 that CMQ was superior to HCQ in reversing vemurafenib 
45 resistance, the combination of CMQ plus vemurafenib only 
46 modestly outperformed the combination of HCQ plus 
47 vemurafenib in vivo, as both combinations worked similarly 
48 at slowing tumor growth (Figure 6). Furthermore, despite 
49 efforts to maintain vemurafenib resistance in our xenograft 
50 model, we observed a partial re-establishment of vemur- 
51 afenib sensitivity, which may have masked differences in 
52 the combinatorial efficacy of the added quinolones. We 
53 anticipate that inclusion of a HQ-resistant tumor model, 
such as the 1205 Lu xenograft model shown by McAfee and 1 
colleagues to be refractory to HCQ as a single agent13 might 2 
also  exasperate  efficacy   differences  between   CMQ  and 3 
HCQ  in   combination  therapy  experiments.  Additionally, 4 
more suitably powered experiments and/or a larger  panel of 5 
cancer cell lines might reveal more profound differences in 6 
CMQ anti-tumor activity  compared to HCQ. 7 
Recent  studies  have  highlighted  a connection between 8 
cancers   with   mutations   in   canonical   Ras/Raf/Mek/Erk 9 
signaling   pathways   and   increased   tumorigenesis that  is 10 
fueled  by  autophagy.46–50  These  findings  prompt  further 11 
evaluation  of  lysosomotropic  inhibitors  of  autophagy  in 12 
cancers   possessing   these   mutations,   which account  for 13 
approximately 30% of all tumors. Further  investigation into 14 
the  effects  of  CMQ  treatment  in  such  tumor  types  is 15 
warranted. 16 
17 
18 
ACKNOWLEDGMENTS 19 
The authors would  like  to thank the staff of  the University 20 
of Vermont Mass Spectrometry Facility and the University 21 
of Vermont Larner College of Medicine Flow  Cytometry & 22 
Sorting   Facility   for   technical   assistance.   The   studies 23 
reported   herein   were   supported   by   the  Irvin  Krakoff 24 
Professor   of   Medicine   Endowment   (awarded to  CFV), 25 
SPARK-VT  program  (awarded  to  JER  and   CFV),  Lake 26 
Champlain  Cancer  Research  Organization  Research  Fel- 27 
lowship  (awarded  to EAH), Nazarbayev University ORAU 28 
grant for Medicinal Electrochemistry (awarded to KL) and 29 
the  Ministry  of  Education  and  Science  of  Kazakhstan 30 
(awarded to KL). 31 
32 
33 
CONFLICTS OF INTEREST 34 
35 
The authors declare no potential conflicts  of interest. 36 
37 
38 
ORCID 39 
Jon E. Ramsey  http://orcid.org/0000-0001-6349-902X 40 
41 
42 
43 
REFERENCES 44 
1. Yang S, et al. Pancreatic Q5cancers require autophagy for tumor 45
growth. Genes Dev. 2011;25:717–729. 46 
2. Fan QW, et al. Akt and autophagy cooperate to promote survival of 47
drug-resistant glioma. Sci Signal. 2010;3:ra81. 48 
3. Degenhardt K, et al. Autophagy promotes tumor  cell survival and 49
restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 
2006;10:51–64. 50 
4. Ma  XH,  et  al.  Measurements  of  tumor  cell autophagy  predict 51
invasiveness, resistance to chemotherapy, and survival in mela- 52 
noma. Clin Cancer Res. 2011;17:3478–3489. 53 
1 5. Xie X, White EP, Mehnert JM. Coordinate autophagy and mTOR
2 pathway inhibition enhances cell death in melanoma. PLoS ONE.
3 2013;8:e55096. 
4 6. Carew JS, et al. Targeting autophagy augments the anticancer 
5 activity of the histone deacetylase inhibitor SAHA to overcomeBcr-Abl-mediated drug resistance. Blood. 2007;110:313–322.
6 7. Ma XH, et al. Targeting ER stress-induced autophagy overcomes
7 BRAF inhibitor resistance in melanoma. J Clin Invest. 
8 2014;124:1406–1417. 
9 8. Amaravadi  RK,  Thompson  CB.  The  roles  of  therapy-induced
10 autophagy  and  necrosis  in  cancer  treatment.  Clin  Cancer Res. 
11 2007;13:7271–7279.
12 9. Hollemans M, et al. Accumulation of weak bases in relation to
intralysosomal pH in cultured human skin fibroblasts. Biochim 13 Biophys Acta. 1981;643:140–151. 
14 10. Gabourel JD. Effects of hydroxychloroquine on the growth of
15 mammalian cells in vitro. J Pharmacol Exp Ther. 1963;141: 122–130.
16 11. Seitz C, et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 and 
17 chloroquine synergize to trigger apoptosis via mitochondrial-
18 lysosomal cross-talk. Int J Cancer. 2013;132:2682–2693. 
19 12. Pellegrini P, et al. Acidic Q6extracellular pH neutralizes the 
20 autophagy-inhibiting activity of chloroquine: Implications for
cancer therapies. Autophagy. 2014;10.21 13. McAfee Q, et al. Autophagy inhibitor Lys05 has single-agent 
22 antitumor activity and reproduces the phenotype of a genetic 
23 autophagy deficiency. Proc Natl Acad Sci U.S.A. 2012;109: 
24 8253–8258. 
25 14. Solomon VR, Hu C, Lee H. Design and synthesis of chloroquine
26 analogs with anti-breast cancer property. Eur J Med Chem. 2010; 
27 45:3916–3923.
28 15. Hartinger CG, Dyson PJ. Bioorganometallic chemistry-from
teaching paradigms to medicinal applications. Chem Soc Rev. 29 2009;38:391–401.
30 16. Dubar F, et al. The antimalarial ferroquine: role of the metal and 
31 intramolecular hydrogen bond in activity and resistance. ACS Chem
32 Biol. 2011;6:275–287. 
33 17. Top, S. et al. Synthesis, biochemical properties and molecular
34 modelling studies of organometallic specific estrogen receptor
35 modulators (SERMs), the ferrocifens and hydroxyferrocifens:
evidence for an antiproliferative effect of hydroxyferrocifens on
36 both hormone-Dependent and hormone-Independent Breast cancer 
37 cell lines. Chem− A Euro J. 2003;9:5223–5236. 
38 18. Hartinger CG, Metzler-Nolte N, Dyson PJ. Challenges and 
39 opportunities in the development of organometallic anticancer
40 drugs. Organometallics. 2012;31:5677–5685. 
41 19. Lam K, Geiger WE. Synthesis and anodic electrochemistry of
42 cymanquine and related complexes. J Organomet Chem. 2016;817: 
43 15–20.20. Geiger WE, et al., Patent-Cymanquine Q7compounds and deriva- 44 tives thereof and use thereof, Worldwide, Editor. 2016. 
45 21. Biot C, et al. Synthesis and antimalarial activity in vitro and in vivo 
46 of a new ferrocene-chloroquine analogue. J Med Chem. 1997;40: 
47 3715–3718. 
48 22. Verschraegen CF, et al. Specific organ metastases of human 
49 melanoma cells injected into the arterial circulation of nude mice.
50 Anticancer Res. 1991;11:529–535.
51 23. Ishiguro K, Ando T, Goto H. Novel application of 4-nitro-7-(1-
piperazinyl)-2, 1, 3-benzoxadiazole to visualize lysosomes in live52 cells. Biotechniques. 2008;45:465, 467–468. 
53 
24. Sheen JH, et al. Defective regulation of autophagy upon leucine 1 
deprivation reveals a targetable liability of human melanoma cells 2 
in vitro and in vivo. Cancer Cell. 2011;19:613–628. 3 
25. Qiao S,  et al.  A REDD1/TXNIP  pro-oxidant  complex regulates 4 
ATG4B activity to control stress-induced autophagy and sustain 5 exercise capacity. Nat Commun. 2015;6:7014.
26. Jackson   WT,   et   al.   Subversion   of  cellular  autophagosomal 6 
machinery by RNA viruses. PLoS Biol. 2005;3:e156. 7 
27. Wu K, et al. Anodic properties of diarylethene derivatives having 8 
organometallic  piano-stool  tags.  Chem  Commun (Camb). 2011; 9 
47:10109–10111. 10 
28. King  MA,  Ganley  IG,  Flemington  V.  Inhibition of cholesterol 11 
metabolism underlies synergy between mTOR pathway inhibition 12 
and chloroquine in bladder cancer  cells.  Oncogene.  2016;35: 4518–
4528. 13 
29. Eng CH, et al. Macroautophagy is dispensable for growth of KRAS 14 
mutant tumors and chloroquine efficacy. Proc Natl Acad Sci U.S.A. 15 
2016;113:182–187. 16 
30. Kabeya  Y,  et  al.  LC3,  GABARAP  and  GATE16  localize  to 17 
autophagosomal membrane depending on form-II formation. J Cell 18 
Sci. 2004;117:2805–2812. 19 
31. Mizushima N,  Yoshimori T,  Levine  B.  Methods in mammalian 20 autophagy research. Cell 2010;140:313–326.
32. Mizushima N.  Methods for  monitoring autophagy. Int J Biochem 21 
Cell Biol. 2004;36:2491–2502. 22 
33. Smalley KS, et al. Multiple signaling pathways must be targeted to 23 
overcome  drug  resistance  in  cell  lines  derived from melanoma 24 
metastases. Mol Cancer Ther. 2006;5: 1136– 1144. 25 
34. Hather G, et al. Growth rate analysis and efficient experimental 26 
design for tumor xenograft studies. Cancer Inform. 2014;13:65–72. 27 
35. Barnard RA, et al. Phase I clinical trial and pharmacodynamic 28 
evaluation of combination hydroxychloroquine  and  doxorubicin
treatment   in   pet   dogs   treated   for   spontaneously   occurring 29 
lymphoma. Autophagy. 2014;10:1415–1425. 30 
36. Rangwala R,  et  al.  Combined  MTOR and autophagy inhibition: 31 
phase I trial of hydroxychloroquine and temsirolimus in patients 32 
with    advanced    solid    tumors    and   melanoma.   Autophagy. 33 
2014;10:1391–1402. 34 
37. Rangwala R, et al. Phase I trial of hydroxychloroquine  with dose- 35 
intense temozolomide in patients with advanced solid tumors and
melanoma. Autophagy. 2014;10:1369–1379. 36 
38. Rosenfeld MR, et al. A phase I/II trial of hydroxychloroquine in 37 
conjunction with radiation therapy and concurrent and adjuvant 38 
temozolomide  in  patients  with  newly  diagnosed  glioblastoma 39 
multiforme. Autophagy. 2014;10:1359–1368. 40 
39. Vogl DT, et al. Combined autophagy and proteasome inhibition: a 41 
phase 1 trial of hydroxychloroquine and bortezomib in patients with 42 
relapsed/refractory myeloma. Autophagy. 2014;10:1380–1390. 43 
40. Held J, et al.  Ferroquine  and  artesunate  in  African  adults  and children 
with Plasmodium falciparum malaria: a phase 2, multi- 44 
centre,   randomised,   double-blind, dose-ranging,  non-inferiority 45 
study. Lancet Infect Dis. 2015;15:1409–1419. 46 
41. McCarthy JS, et al. A Phase II pilot trial to evaluate safety and 47 
efficacy of ferroquine against early  Plasmodium falciparum in an 48 
induced blood-stage malaria infection study. Malar J. 2016;15: 49 
469. 50 
42. Biot C, et al. Insights into the mechanism of action of ferroquine. 51 Relationship between physicochemical properties and antiplasmo- 
dial activity. Mol Pharm. 2005;2: 185– 193. 52 
53 
1 43. Foley M, Tilley L. Quinoline antimalarials: mechanisms of  action
2 and  resistance  and  prospects  for  new  agents.  Pharmacol Ther. 
3 1998;79:55–87. 
4 44. Fox RI. Mechanism of action of hydroxychloroquine as an 
5 antirheumatic drug. Semin Arthritis Rheum. 1993;23:82–91. 45. Lamphier M, et al. Novel small molecule inhibitors of TLR7 and TL
6 R9: mechanism of action and efficacy in vivo. Mol Pharmacol. 7 2014;85:429–440. 
8 46. Schmitz KJ, et al. Pognostic relevance of autophagy-related 
9 markers LC3, p62/sequestosome 1, Beclin-1 and ULK1 in
10 colorectal cancer patients with respect to KRAS mutational status. 
11 World J Surg Oncol. 2016;14:189. 
12 47. Giatromanolaki A, et al. Autophagy and lysosomal related protein
expression patterns in human glioblastoma. Cancer Biol Ther.13 2014;15:1468–1478.
14 48. Giatromanolaki A, et al. Autophagy proteins in prostate cancer: 
15 relation with anaerobic metabolism and Gleason score. Urol Oncol.
16 2014;32: 39 e11–e18. 
17 49. Choi J, Jung W, Koo JS. Expression of autophagy-related markers 
18 beclin-1, light chain 3A, light chain 3B and p62 according to the 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
molecular subtype of breast cancer. Histopathology. 1 
2013;62:275–286. 2 
50. Goulielmaki M, et al. BRAF associated autophagy exploitation: 3 
bRAF and autophagy inhibitors synergise to  efficiently overcome 4 
resistance  of  BRAF  mutant  colorectal  cancer cells. Oncotarget 5 
2016;7:9188–9221. 
6
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
P 
1 Graphical Abstract 1 
2 2 
3 The contents of this page will be used as part of the graphical abstract of html only. It will not be published as part of main. 3 
4 4 
5 5 
6 6 
7 7 
8 8 
9 9 
10 10 
11 11 
12 12 
13 13 
14 14 
15 15 
16 16 
17 17 
18 18 
19 19 
20 20 
21 21 
22 22 
23 23 
24 The cellular process of autophagy has emerged as a viable target in the treatment of many tumor types. Efforts are underway to 24 
25 optimize the anti-malarial compound, chloroquine, to improve its ability to block autophagy in the fight against cancer. Here, we 25 
26 report a novel organometallic derivative of chloroquine, termed Cymanquine, that displays improved anti-autophagy properties, 26 
27 and the capacity to slow tumor growth  in vivo. 27 
28 28 
29 29 
30 30 
31 31 
32 32 
33 33 
34 34 
35 35 
36 36 
37 37 
38 38 
39 39 
40 40 
41 41 
42 42 
43 43 
44 44 
45 45 
46 46 
47 47 
48 48 
49 49 
50 50 
51 51 
52 52 
53 53 
